Five drugmakers rule out China military-site trials, US House panel says


Merck, Eli Lilly, Pfizer and Bristol Myers Squibb also agreed not to start new trials in Xinjiang, while AbbVie cited its duty to patients there, a US congressional committee said.
Merck, Eli Lilly, AbbVie, Pfizer and Bristol Myers Squibb said they would not start new clinical trials at sites linked to China’s People’s Liberation Army, the US House Select Committee on China disclosed, STAT reported. The committee opened investigations into the five drugmakers in June 2026 over concerns about intellectual property, military ties and research ethics at trial sites in China.
All except AbbVie also agreed not to start new trials in Xinjiang. The commitments concern new trials; they do not establish that ongoing studies will stop.
AbbVie cited a duty to provide potentially lifesaving treatment to patients in Xinjiang, the committee said. Company officials said most of those patients were cancer patients in a critical state of disease.
China’s government has targeted Uyghurs and other ethnic and religious minorities in Xinjiang. The committee’s letters said Chinese researchers had documented lapses in obtaining informed consent, meaning participants agree to a trial after receiving information about it.
Committee chair John Moolenaar, a Republican representative, asked Merck and AbbVie in letters dated 29 June for details about checks, data protection and other standards at their Chinese trial sites by 17 July. The committee also sent letters to the other three companies,
The letters said research at Chinese military hospitals risked transferring US biotechnology intellectual property to the Chinese military. They also said there was no evidence that Merck or AbbVie had engaged in illegal activity or wrongdoing. A spokesperson for China’s embassy in the US said there was “nothing credible” in the committee’s actions and that China opposed politicizing trade and technology issues.
STAT said on 20 November 2026, that the committee planned to release a report on its findings that day.
After falling 95% between 2011 and 2017, annual forest clearing for pulpwood plantations in Indonesia rose from about 5,600 hectares in 2017 to 24,300 in 2022, a study found. Researchers warn that expanding pulp mills could put more forest and peatland at risk.
4 min

The cloud around Jupiter’s moon has changed little over more than two decades. Co-author Carl Schmidt says its stability points to Europa’s saltwater, rather than the volcanoes of neighboring Io, as the source of the sodium.
3 min

The nonprofit says citations need further review after Science alleged that 10 references contained apparently fabricated co-author first names.
3 min